Please login to the form below
evolucumab
This page shows the latest evolucumab news and features for those working in and with pharma, biotech and healthcare.
Amgen's Repatha unclogs blocked arteries, says study
Looks to boost sales after trial shows clear clinical advantage of PCSK9 inhibitor over statins
Latest news
-
SMC rejects Amgen's Repatha over lack of outcomes data
But gives GlaxoSmithKline’s asthma drug Nucala the green light. The Scottish Medicines Consortium (SMC) has turned down Amgen's cholesterol-lowering treatment Repatha (evolucumab), citing a lack of “robust” data.
-
NICE persuaded to back Praluent as well as Repatha
drug. The scheme includes an undisclosed discount to the NHS and allows NICE to back Praluent and Amgen's rival Repatha (evolucumab), which had already agreed a price cut, in new
More from news
Approximately 3 fully matching, plus 0 partially matching documents found.
Featured jobs
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Account Director
-
Competitive Salary Offered
-
Account Director, Medical Education
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Associate Director
-
£75, 000-90, 000
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Global Business Development Director – Health Education
-
excellent commission
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Business Director
-
Competitive Salary Offered
-
Senior Medical Writer
-
Salary TBC
-
Medical Writer
-
Salary TBC
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Manager / Account Director
-
Competative
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
Subscribe to our email news alerts
- Pfizer takeover rumour ignites Amarin shares
- Welcome to the Communique Awards - Communiqué Awards 2018
- NICE rejects Novartis migraine treatment Aimovig
- AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
- GSK upbeat on its return to oncology market
- BMS and Celgene deal sparks debate on pharma profit motive, more M&A
- The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
- The UK’s new five-year pricing agreement
- Lucid kick-starts 2019 with spellbinding new additions to its writing and account teams
- New hires at Nanoform, Leo Pharma and Calliditas
- Page & Page welcomes Clare Bates to the team
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
PMHub
Publicis Resolute
Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...
Latest intelligence
- The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
- ...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again – in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
